43results about How to "Specific binding" patented technology

The invention discloses a carbendazim monoclonal antibody, a preparation method and an application thereof. The carbendazim monoclonal antibody is prepared by a mouse hybridoma cell strain MC-3 with a preservation number of CGMCC N0.4575 and the preparation method is as follows: (1) introducing ninth amino acid residue of carbendazim into one amino group to obtain the carbendazim modified by the amino and coupling the carbendazim modified by the amino with a carrier protein to obtain a complete antigen A; (2) immunizing a mouse by the complete antigen A obtained in step (1), taking splenocyteof the immune mice to fuse with a mouse myeloma cell to screen out a positive hybridoma cell strain; extensively culturing the positive hybridoma cell strain and injecting the positive cell strain into a homologous mouse abdominal cavity to induce to generate ascitic fluid and to obtain more carbendazim monoclonal antibodies. The Carbendazim monoclonal antibody can be used for detecting the carbendazim.

The invention belongs to the technical field of soil protection, in particular to a remediation method for heavy metal pollution of farmland soil. A heavy metal passivator is uniformly mixed with soil, after conservation, the first crop is planted, and then hyperaccumulators are planted, at that same time, a heavy metal activator is applied and the passivator is applied, after the second crop is planted, the heavy metal passivator is applied at first, so as to reduce the risk of heavy metal leaching, at that same time, heavy metals are avoided to be enriched in crops, and then the heavy metalactivator is applied to plant hyperaccumulators to absorb heavy metals and reduce the content of heavy metals in the soil, and the heavy metals in the soil not covered by the plant roots are kept at alow leaching risk due to the existence of heavy metal passivators. The invention adopts a plant enrichment technology and a method of applying a heavy metal passivator, which can not only fundamentally remove the problem of heavy metals, but also passivate the heavy metals when planting crops, thereby improving the use efficiency of the soil.

The present invention discloses a nucleic acid construct. The nucleic acid construct is characterized in that the nucleic acid construct has a structure as shown in the formula car-[(IRES)-f]<m>, wherein the IRES is a sequence of an internal ribosome entry site, f encodes a functional protein F, m is 0 or a non-0 natural number, car encodes a CAR, the CAR comprises (a) an extracellular binding domain that specifically recognizes CLDN18.2, (b) a hinge domain, (c) a transmembrane domain, (d) a costimulating intracellular domain, and (e) a signal transduction domain, the extracellular binding domain comprises scFv, and the amino acid sequences and functions of the extracellular binding structural domain are described in the specification. The CAR molecule provided by the invention has excellent safety and effectiveness and shows a very good tumor inhibition effect.

The invention discloses variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies. The amino acid sequence of a monoclonal antibody light chain variable region is shown as SEQ ID NO.1, and the amino acid sequence of a monoclonal antibody heavy chain variable region is shown as SEQ ID NO.2. A set of mouse anti-human EPCAM monoclonal antibodies are prepared through recombining human EPCAM immune BALB/c mice, and hybridoma cell lines capable of stably secreting high-affinity anti-human EPCAM monoclonal antibodies are screened to prepare ascitic fluid so as to obtain the high-affinity anti-human EPCAM monoclonal antibodies. The uniqueness of the gene sequence and a corresponding protein sequence and a CDR sequence of the gene sequence are confirmed so as to provide supports for anti-human EPCAM chimeric or humanized gene engineering antibodies.

The invention relates to a fusion protein of an IFN and an anti-PD-L1 antibody, a pharmaceutical composition containing the fusion protein and a kit as well as an application of the fusion protein intumor treatment. The fusion protein can be targeted to PD-L1 and IFN receptors at the same time. An IFN signal in a tumor microenvironment is activated by inducing more powerful T cell activation to enhance PD-1/PD-L1 treatment on tumors; meanwhile, the anti-PD-L1 antibody can be used for specifically transferring immunoregulation molecules to tumor tissues. The fusion protein acts to generate multiple feedforward responses, so that the targeting effect is increased and the toxicity is reduced, and response to IFN treatment is enhanced, so that the anti-tumor effect is maximized.

The present invention discloses preparation and application of a hepatitis C virus (HCV) recombinant protein, specifically discloses a separated HCV antigen peptide, which is derived from an E2 protein of HCV virus; the antigenic peptide can bind to an anti-HCV antibody; and the HCV is a Con1 strain of HCV 1b genotype. The invention provides a composition containing the above antigen peptide and a preparation method thereof. The HCV antigen peptide of the invention can effectively and specifically combine with anti-E2 antibody in serum of an infected patient in a broad-spectrum way, and can be used to develop a diagnostic kit for the detection of HCV infection.

The invention refers to a zinc protein and the antibody, relative to human hematogenic system growth. The ZNF 268 protein is a typical krIIppel-type C2H2 zinc protein; the preparation mainly structures ZNF268 expression carrier, transfers into host cells to express and separate to purify ZNF268 protein; the protein can diagnose and treat the disease because of protein abnormity. The antibody of ZNF268 protein can exceptionally combine with ZNF268 protein. The antibody preparation; mix the ZNF268 protein and assist agent to immunize animal, then separate the immune antimal blood to purify the antibody; the antibody; the antibody can diagnose, treat or prevent the disease relative to the protein abnormity of ZNF268 protein.

The invention belongs to the technical field of antibodies and discloses a method for preparing PD-L1 (programmed death-ligand 1) nanoantibody by immunizing alpacas with a PD-L1 antigen. The method comprises: designing two synthetic primers, amplifying by PCR (polymerase chain reaction) to obtain sufficient target products for enzyme digestion, linking target fragments to a vector, converting, and carrying out screening and cloning; carrying out protein verifying and expressing; constructing an antibody library; displaying a VHH antibody library through an M13 bacteriophage display system which is composed of a pMECS phagemid vector, E. coli TG1 and an M13KO7 helper phage. In the phasmid vector pMECS, a sequence before a Pst I enzyme digestion site is a coding sequence for part of amino acids in first frame regions of pelB secretory signal peptides and antibodies; the pelB signal peptides can guide subsequent polypeptides secreted to periplasmic cavities; a sequence after a Not I enzyme digestion site is a coding sequence for HA and 6*His tags; the method is suitable for purification or detection of fusion proteins.

The present invention provides a “nucleic acid adaptor molecule” having specific binding affinity to a GST protein portion serving as an N-terminal fusion partner in a fusion protein consisting of the GST protein and a protein of interest. A “nucleic acid adaptor molecule against a GST protein” according to the present invention is an RNA aptamer molecule having any of the following nucleotide sequences I to III:

The invention discloses an anti-procalcitonin nano antibody. The anti-procalcitonin nano antibody has three unique complementary determining regions CDR1, CDR2, and CDR3. The invention also provides an expression vector containing the variable region coding sequence of the nano antibody, host cells containing the expression vector, a fusion protein of the nano antibody and alkaline phosphatase, and an application of the nano antibody in preparation of a procalcitonin detection kit. The anti-procalcitonin nano antibody provided by the invention has specific recognition and binding capacity on procalcitonin, the affinity with antigen can reach 7.429 E-9, and an excellent detection effect is obtained in procalcitonin detection, especially in application of a double-antibody sandwich method.

The present invention relates to a novel silica gel material capable of recognizing N-phosphopeptides and proteins under neutral conditions and application thereof in N-phosphopeptide and protein enrichment. Non-porous silica microspheres are prepared by a seed growth method, a core-shell microsphere initial layer is formed by a template-guided dissolution and re-deposition method, and finally sub-2-micron core-shell silica gel with vertical pores can be obtained by acid reflux. N-tert-butyloxycarbonyl-L-tyrosine and N, N'-dipicolylamine are reacted to form a support molecule, and a phosphaterecognition functional molecule is formed by complexation of a metal ion on the support molecule. Finally, the novel phosphoric acid recognition functional silica gel material is obtained by covalently bonding the phosphoric acid recognition functional molecule with the sub-2-micron core-shell silica gel having the vertical pores through an amide bond. The novel phosphoric acid recognition functional silica gel material can rapidly and specifically enrich the N-phosphopeptides and proteins in a neutral buffer system.

The invention discloses a single domain antibody for resisting CEACAM-5. The single domain antibody has three unique complementary determining regions CDR1, CDR2 and CDR3. The invention further provides an expression vector containing a variable region coding sequence of the single domain antibody, a host cell containing the expression vector, fusion protein of a variable region of the single domain antibody and human alkaline phosphatase, application of the single domain antibody in preparing a CEACAM-5 detection kit, a method for CEACAM-5 immunological detection by applying the single domainantibody as well as a corresponding detection kit. The single domain antibody for resisting the CEACAM-5, provided by the invention, has specific recognizing and binding capability for the CEACAM-5;the affinity of the single domain antibody can reach 4.51E-09; the single domain antibody has unique antigenic determinant recognition site and can obtain an excellent detection result in CEACAM-5 immunological detection, in particular to a double antibody sandwich method.

The present invention discloses an anti-anthrax PA antigen monoclonal antibody having a humanize form, a chimeric form and a murine form, and applications of the monoclonal antibody in anthrax treatment drug preparation. The anti-anthrax PA antigen monoclonal antibody has characteristics of specific antigen binding, excellent toxin neutralization activity and good animal protection function.

The invention discloses a monoclonal antibody resistant to different structural domains of a SasA (staphylococcus aureus surface protein A) antigen as well as an application of the monoclonal antibody in preparation of a drug for resisting staphylococcus aureus infection. The specific antibody has good protection performance in a mouse model when in combined utilization.

The invention relates to a monomolecular protein detection chip and a monomolecular protein detection method based on ultramicro electrode array electrochemiluminescence. The monomolecular protein detection chip is provided with a substrate of an ITO (indium tin oxide) electrode and an inclined micro trap array with a three-dimensional concave part on the ITO electrode, the two ends of the inclined micro trap array in the transverse direction are respectively provided with wires connected with the positive electrode and the negative electrode of a power supply. The single-molecule protein detection chip is simple to prepare, an electrochemical luminescence detection system further amplifies a signal, and high-sensitivity single-molecule detection of trace protein can be realized.

The invention provides a monoclonal antibody capable of resisting helicobacter pylori protein, and a cell line, a preparation method and application thereof. The ultrasound supernatant part of cultured helicobacter pylori mycoprotein is taken as immunogen to immunize a mice, an antibody15A5 capable of specifically combining with the helicobacter pylori protein is obtained after screening, and theantibody is an IgG2a subtype. The antibody can be used for detecting the infected helicobacter pylori in tissues or serum.

The invention discloses a light-chain variable region and a heavy-chain variable region of an FMU-EPCAM-4F6 monoclonal antibody, wherein an amino acid sequence of the light-chain variable region of the FMU-EPCAM-4F6 monoclonal antibody is shown as SEQ ID NO.1, and an amino acid sequence of the heavy-chain variable region of the FMU-EPCAM-4F6 monoclonal antibody is shown as SEQ ID NO.2. In the invention, a group of mouse anti-human EPCAM monoclonal antibodies is prepared by a recombinant human EPCAM immune BALB/c mouse, hybridoma cell strains which can stably secrete high-affinity anti-human EPCAM monoclonal antibodies are screened, and the high-affinity anti-human EPCAM monoclonal antibodies are obtained by preparing ascitic fluid. The invention confirms the uniqueness of a gene sequence and a corresponding protein sequence as well as a CDR sequence and provides support for anti-body EPCAM chimeric or humanized gene engineering antibodies.